Ginkgo Bioworks (NYSE:DNA – Get Free Report) and Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.
Profitability
This table compares Ginkgo Bioworks and Cidara Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ginkgo Bioworks | -298.78% | -58.54% | -34.24% |
| Cidara Therapeutics | -289.05% | -69.64% | -33.73% |
Analyst Ratings
This is a summary of current ratings and price targets for Ginkgo Bioworks and Cidara Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ginkgo Bioworks | 3 | 1 | 1 | 0 | 1.60 |
| Cidara Therapeutics | 0 | 0 | 5 | 1 | 3.17 |
Earnings and Valuation
This table compares Ginkgo Bioworks and Cidara Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ginkgo Bioworks | $217.11 million | 2.67 | -$892.87 million | ($13.08) | -0.77 |
| Cidara Therapeutics | $44.65 million | 3.66 | -$22.93 million | ($25.52) | -0.91 |
Cidara Therapeutics has lower revenue, but higher earnings than Ginkgo Bioworks. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Ginkgo Bioworks has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
Institutional and Insider Ownership
78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 7.6% of Cidara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Cidara Therapeutics beats Ginkgo Bioworks on 8 of the 15 factors compared between the two stocks.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
About Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
